Company intelligence / Profile preview

Qvin

Menlo Park, California, United Statesqvin.com ↗

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

Qvin has developed the first FDA-cleared diagnostic device that uses menstrual blood for health testing. Its initial commercial product measures HbA1c for diabetes monitoring using a non-invasive pad-based sample collection method. Clinical studies have shown strong correlation between biomarkers measured from menstrual blood collected by the Q-Pad and traditional venous samples. The company’s technology has also received regulatory approval in Thailand for cervical cancer screening via HR‑HPV detection.

Therapeutic areas: EndocrinologyWomen's Health
Modalities: DeviceDiagnostic device (specifically, menstrual blood collection and analysis)
Industry: Molecular Diagnostics

Partnerships

KindbodyAxia HealthStanford Medical SchoolHarvard Medical School

Beyond the preview

Go deeper on Qvin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qvin.

Explore the full profile